BURLINGTON, Mass.–(BUSINESS WIRE)– Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per…Read More
Bone Biologics Announces Registered Direct Offering Priced AttheMarket Under Nasdaq Rules
